Peter Miles Irving
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Miles Irving has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Mark A. Samaan
IBD Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
29 shared publications - Kevin Whelan
Department of Nutritional Sciences King's College London London UK
24 shared publications - Christopher Andrew Lamb
Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
19 shared publications - Charlie W. Lees
Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, UK
17 shared publications - Miranda Clare Elizabeth Lomer
Department of Nutritional Sciences King's College London London UK
17 shared publications - Nicholas Alexander Kennedy
IBD Research Group, University of Exeter, Exeter, UK
17 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (10)
Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn’s disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment
Background & Aims: Patient-reported outcomes (PRO) are essential for monitoring disease activity and treatment response in inflammatory bowel disease (IBD). The conventional PRO-2 requires several days of prospective symptom recording, increasing participant burden and attrition in longitudinal research. We evaluated whether a “rapid PRO-2”, using 2 days of data collected retrospectively and prospectively in a single day, could serve as a reliable and pragmatic alternative to a 4-day PRO-2. Methods: Using data from the ongoing IBD-RESPONSE cohort (n = 684 Crohn’s disease [CD]; n = 548 ulcerative colitis [UC]), we compared 4-day PRO-2 and rapid PRO-2 scores at baseline and 14 weeks post-therapy to assess disease activity, clinical (non) response and remission. Results: At baseline, 87.1% (596/684) of CD and 88.7% (486/548) of UC patients remained in the same active/inactive disease activity category (Cohen’s kappa: CD 0.715; UC 0.762; both P < .001). At week 14, 77% (CD; 195/252) and 83.1% (UC; 193/232) remained in the same non-response/response/remission category (Cohen’s kappa: CD 0.653; UC 0.743; both P < .001). Discrepancies mainly involved adjacent category shifts (ie, between response and remission, or non-response and response), with minimal re-classification between remission and non-response (n = 7 CD and n = 2 UC). Greater symptom variability across the 4 days increased the likelihood of switching between remission and non-response (odds ratio [95% confidence interval], CD 5.0 [3.65–6.85]; UC 7.8 [5.6–11.0], both P < .001). Responsiveness to clinical change was comparable between instruments. Conclusions: The rapid PRO-2 retains essential symptom data and demonstrates strong agreement with the 4-day PRO-2, offering an alternative in longitudinal studies to minimize burden and attrition.
- 9 October 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (10)
Open AccessLongitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn’s disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment
Background & Aims: Patient-reported outcomes (PRO) are essential for monitoring disease activity and treatment response in inflammatory bowel disease (IBD). The conventional PRO-2 requires several days of prospective symptom recording, increasing participant burden and attrition in longitudinal research. We evaluated whether a “rapid PRO-2”, using 2 days of data collected retrospectively and prospectively in a single day, could serve as a reliable and pragmatic alternative to a 4-day PRO-2. Methods: Using data from the ongoing IBD-RESPONSE cohort (n = 684 Crohn’s disease [CD]; n = 548 ulcerative colitis [UC]), we compared 4-day PRO-2 and rapid PRO-2 scores at baseline and 14 weeks post-therapy to assess disease activity, clinical (non) response and remission. Results: At baseline, 87.1% (596/684) of CD and 88.7% (486/548) of UC patients remained in the same active/inactive disease activity category (Cohen’s kappa: CD 0.715; UC 0.762; both P < .001). At week 14, 77% (CD; 195/252) and 83.1% (UC; 193/232) remained in the same non-response/response/remission category (Cohen’s kappa: CD 0.653; UC 0.743; both P < .001). Discrepancies mainly involved adjacent category shifts (ie, between response and remission, or non-response and response), with minimal re-classification between remission and non-response (n = 7 CD and n = 2 UC). Greater symptom variability across the 4 days increased the likelihood of switching between remission and non-response (odds ratio [95% confidence interval], CD 5.0 [3.65–6.85]; UC 7.8 [5.6–11.0], both P < .001). Responsiveness to clinical change was comparable between instruments. Conclusions: The rapid PRO-2 retains essential symptom data and demonstrates strong agreement with the 4-day PRO-2, offering an alternative in longitudinal studies to minimize burden and attrition.
- Open Access
- 1 October 2026
- Published by BMJ in Frontline Gastroenterology
Best-practice recommendations for the transition care pathway for children and young people with moderate to severe ulcerative colitis: a modified Delphi panel with UK health care professionals
Objective: In the UK, the incidence of paediatric-onset ulcerative colitis (UC) is rising. UC is incurable, thus paediatric patients will require transfer to adult healthcare services. Effective transition is critical for continuity of good care while optimising treatment outcomes; however, transitional care currently varies across the UK. We aimed to develop UK consensus recommendations to facilitate optimal management of children and young people with moderately to severely active UC transitioning from paediatric to adult care. Design/Method: A modified Delphi, following the ACcurate COnsensus Reporting Document for Delphi research was conducted. Current clinical guidelines, treatment and transition pathways, pathway implementation and limitations were evaluated. A panel, comprising paediatric and adult gastroenterologists, plus paediatric gastroenterology specialist nurses, most with over 15 years of individual experience managing UC, participated in two anonymous online surveys and an online consensus conference to develop recommendations. Results: The Delphi study identified key areas for improvement, including the need for early preparation, tailored implementation and the integration of digital health resources. Consensus (agreement ≥75%) was achieved on the importance of structured transition pathways, developmentally appropriate guidance, joint clinics and the various healthcare professionals who should be involved in the transition process. The study highlighted potential barriers to the use of advanced therapies and the need for updated management guidelines. Conclusion: The consensus recommendations developed provide a framework for optimising the transition pathway for children and young people with UC moving to adult care, to improve outcomes and ensure continuity of care during this critical period.
- 1 October 2026
- Published by BMJ in Frontline Gastroenterology
Open AccessBest-practice recommendations for the transition care pathway for children and young people with moderate to severe ulcerative colitis: a modified Delphi panel with UK health care professionals
Objective: In the UK, the incidence of paediatric-onset ulcerative colitis (UC) is rising. UC is incurable, thus paediatric patients will require transfer to adult healthcare services. Effective transition is critical for continuity of good care while optimising treatment outcomes; however, transitional care currently varies across the UK. We aimed to develop UK consensus recommendations to facilitate optimal management of children and young people with moderately to severely active UC transitioning from paediatric to adult care. Design/Method: A modified Delphi, following the ACcurate COnsensus Reporting Document for Delphi research was conducted. Current clinical guidelines, treatment and transition pathways, pathway implementation and limitations were evaluated. A panel, comprising paediatric and adult gastroenterologists, plus paediatric gastroenterology specialist nurses, most with over 15 years of individual experience managing UC, participated in two anonymous online surveys and an online consensus conference to develop recommendations. Results: The Delphi study identified key areas for improvement, including the need for early preparation, tailored implementation and the integration of digital health resources. Consensus (agreement ≥75%) was achieved on the importance of structured transition pathways, developmentally appropriate guidance, joint clinics and the various healthcare professionals who should be involved in the transition process. The study highlighted potential barriers to the use of advanced therapies and the need for updated management guidelines. Conclusion: The consensus recommendations developed provide a framework for optimising the transition pathway for children and young people with UC moving to adult care, to improve outcomes and ensure continuity of care during this critical period.
- Open Access
- 31 May 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes
Background: VEST was a multi-centre study of real-world use of vedolizumab in inflammatory bowel disease (IBD) in routine practice in the United Kingdom. Objectives: To describe real-world indications, effectiveness, patient-reported outcomes and safety. Design: Prospective observational cohort study at 22 centres. Methods: Patients receiving vedolizumab as part of standard care were included. Data were collected at infusion visits for activity indices (Harvey–Bradshaw Index (HBI) or partial Mayo Score (PMS)), physician global assessment (PGA), patient-reported quality-of-life and treatment perception (IBD-Control Questionnaire) and adverse events. Clinical response (Wk14) was defined as a reduction in HBI ⩾3 or PMS ⩾2, clinical remission as HBI ⩽4 or PMS ⩽1 and analysed using non-responder imputation. One-year persistence was defined as continuing on vedolizumab after an infusion at ⩾48 weeks. Biomarker and endoscopic data were not available. Results: 364 patients, mean age: 48 years; 132 (36%) with Crohn’s disease (CD), 224 (62%) with UC and 8 (2%) with IBD-U; 174 (48%) male; 142 (39%) receiving steroids at baseline (Wk0); 141 (39%) bio-naïve. At baseline, 279 (77%) had “active” disease. One-year persistence: 58% overall (54% for active disease). Among persistent cases ( n = 212), median (IQR) IBD-Control-8 scores improved from 6 (3–10) at baseline to 14 (10–16) at post-induction (Wk14) and 1 year ( p < 0.001 vs baseline). Corresponding scores for IBD-Control-VAS were: 50 (30–70), 80 (65–90) and 85 (70–95), respectively ( p < 0.001 vs baseline). Each domain of IBD-Control-8 showed improvement. Baseline and post-induction health status (activity index, PGA or IBD-Control) were associated with 1-year persistence, but no significant associations were observed for disease type, duration, bio-naïve status or baseline steroids. Of those with active disease at Wk0, clinical remission rates were 29%, 30% and 38% for CD, UC and IBD-U, respectively, and steroid-free remission rates were 26%, 27% and 38%. Similar remission rates were observed at 1 year. Possible adverse events leading to treatment cessation were rare (3%). Conclusion: In routine clinical practice in the UK, vedolizumab demonstrated high levels of persistence. Similar rates of clinical response, remission and 1-year persistence were seen in UC and CD patients, and in bio-experienced versus naïve cases. Persistent cases experienced significant and sustained improvements in quality of life and treatment perception. Persistence does not imply anti-inflammatory efficacy, as biomarker data were not available.
- 31 May 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Open AccessThe UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes
Background: VEST was a multi-centre study of real-world use of vedolizumab in inflammatory bowel disease (IBD) in routine practice in the United Kingdom. Objectives: To describe real-world indications, effectiveness, patient-reported outcomes and safety. Design: Prospective observational cohort study at 22 centres. Methods: Patients receiving vedolizumab as part of standard care were included. Data were collected at infusion visits for activity indices (Harvey–Bradshaw Index (HBI) or partial Mayo Score (PMS)), physician global assessment (PGA), patient-reported quality-of-life and treatment perception (IBD-Control Questionnaire) and adverse events. Clinical response (Wk14) was defined as a reduction in HBI ⩾3 or PMS ⩾2, clinical remission as HBI ⩽4 or PMS ⩽1 and analysed using non-responder imputation. One-year persistence was defined as continuing on vedolizumab after an infusion at ⩾48 weeks. Biomarker and endoscopic data were not available. Results: 364 patients, mean age: 48 years; 132 (36%) with Crohn’s disease (CD), 224 (62%) with UC and 8 (2%) with IBD-U; 174 (48%) male; 142 (39%) receiving steroids at baseline (Wk0); 141 (39%) bio-naïve. At baseline, 279 (77%) had “active” disease. One-year persistence: 58% overall (54% for active disease). Among persistent cases ( n = 212), median (IQR) IBD-Control-8 scores improved from 6 (3–10) at baseline to 14 (10–16) at post-induction (Wk14) and 1 year ( p < 0.001 vs baseline). Corresponding scores for IBD-Control-VAS were: 50 (30–70), 80 (65–90) and 85 (70–95), respectively ( p < 0.001 vs baseline). Each domain of IBD-Control-8 showed improvement. Baseline and post-induction health status (activity index, PGA or IBD-Control) were associated with 1-year persistence, but no significant associations were observed for disease type, duration, bio-naïve status or baseline steroids. Of those with active disease at Wk0, clinical remission rates were 29%, 30% and 38% for CD, UC and IBD-U, respectively, and steroid-free remission rates were 26%, 27% and 38%. Similar remission rates were observed at 1 year. Possible adverse events leading to treatment cessation were rare (3%). Conclusion: In routine clinical practice in the UK, vedolizumab demonstrated high levels of persistence. Similar rates of clinical response, remission and 1-year persistence were seen in UC and CD patients, and in bio-experienced versus naïve cases. Persistent cases experienced significant and sustained improvements in quality of life and treatment perception. Persistence does not imply anti-inflammatory efficacy, as biomarker data were not available.
- Open Access
Resolving inflammatory bowel disease risk variants to genes and cell types
Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
Open AccessResolving inflammatory bowel disease risk variants to genes and cell types
Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (6) , 1023-1040
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
Background: Mirikizumab, an anti-interleukin-23 monoclonal antibody targeting the p19 subunit, has shown efficacy in inducing and maintaining clinical remission in patients with moderately-to-severely active ulcerative colitis (UC). This report summarizes the final long-term outcomes from the LUCENT-3 open-label extension (OLE) through week (W)212 of continuous treatment. Methods: Among 868 participants who received mirikizumab induction therapy in the LUCENT clinical trial program, 544 achieved clinical response. Of these, 365 were rerandomized to mirikizumab maintenance, with 324 completing W52, 316 entering the OLE, and 182 completing the OLE (4 years of continuous treatment), resulting in 835.3 total patient years of exposure. These analyses include efficacy and safety data from the LUCENT-3 cohort, stratified by LUCENT-1 baseline biologic experience, W52 remitter, and W52 responder status on entering the OLE study. Outcomes were analyzed using modified nonresponder imputation, traditional nonresponder imputation, and observed cases (OC) to handle missing data. Results: At W212, W52 Maintenance Remitters showed 77.7% clinical, 77.7% corticosteroid-free (CSF), 81.3% endoscopic, 66.0% histologic-endoscopic mucosal (HEMR), 94.3% symptomatic, and 73.6% bowel urgency (BU) remission rates (OC); 67.9% achieved histologic-endoscopic mucosal improvement (HEMI), 97.1% sustained clinical response, and 92.9% achieved BU clinically meaningful improvement (CMI). At W212, W52 Maintenance Responders showed 68.7% clinical, 68.7% CSF, 70.2% endoscopic, 55.1% HEMR, 92.7% symptomatic, and 74.8% BU remission rates (OC). For W52 Maintenance Completers, reductions in stool frequency, rectal bleeding, bowel urgency, and abdominal pain from baseline were sustained to W212. W52 Maintenance Remitters and Responders achieved Inflammatory Bowel Disease Questionnaire (IBDQ; quality of life measure) response (70%) and remission (>66%) at W212. Across biologic failed and bionaive subgroups, efficacy results were generally similar. For over 160 weeks of OLE treatment in the safety population, no new safety signals emerged from long-term exposure compared with induction and maintenance treatment. Conclusions: Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in responding patients with moderately-to-severely active UC, including those with prior biologic failure. These treatment goals, which are integral to comprehensive disease management, support the long-term use of mirikizumab.
- 2 March 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (6) , 1023-1040
Open AccessMirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
Background: Mirikizumab, an anti-interleukin-23 monoclonal antibody targeting the p19 subunit, has shown efficacy in inducing and maintaining clinical remission in patients with moderately-to-severely active ulcerative colitis (UC). This report summarizes the final long-term outcomes from the LUCENT-3 open-label extension (OLE) through week (W)212 of continuous treatment. Methods: Among 868 participants who received mirikizumab induction therapy in the LUCENT clinical trial program, 544 achieved clinical response. Of these, 365 were rerandomized to mirikizumab maintenance, with 324 completing W52, 316 entering the OLE, and 182 completing the OLE (4 years of continuous treatment), resulting in 835.3 total patient years of exposure. These analyses include efficacy and safety data from the LUCENT-3 cohort, stratified by LUCENT-1 baseline biologic experience, W52 remitter, and W52 responder status on entering the OLE study. Outcomes were analyzed using modified nonresponder imputation, traditional nonresponder imputation, and observed cases (OC) to handle missing data. Results: At W212, W52 Maintenance Remitters showed 77.7% clinical, 77.7% corticosteroid-free (CSF), 81.3% endoscopic, 66.0% histologic-endoscopic mucosal (HEMR), 94.3% symptomatic, and 73.6% bowel urgency (BU) remission rates (OC); 67.9% achieved histologic-endoscopic mucosal improvement (HEMI), 97.1% sustained clinical response, and 92.9% achieved BU clinically meaningful improvement (CMI). At W212, W52 Maintenance Responders showed 68.7% clinical, 68.7% CSF, 70.2% endoscopic, 55.1% HEMR, 92.7% symptomatic, and 74.8% BU remission rates (OC). For W52 Maintenance Completers, reductions in stool frequency, rectal bleeding, bowel urgency, and abdominal pain from baseline were sustained to W212. W52 Maintenance Remitters and Responders achieved Inflammatory Bowel Disease Questionnaire (IBDQ; quality of life measure) response (70%) and remission (>66%) at W212. Across biologic failed and bionaive subgroups, efficacy results were generally similar. For over 160 weeks of OLE treatment in the safety population, no new safety signals emerged from long-term exposure compared with induction and maintenance treatment. Conclusions: Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in responding patients with moderately-to-severely active UC, including those with prior biologic failure. These treatment goals, which are integral to comprehensive disease management, support the long-term use of mirikizumab.
- Open Access
- 8 February 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (6) , 1075-1085
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program
Introduction: Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We evaluated patient-reported symptomatic improvement from patients in the ELEVATE UC program. Methods: This study was a post-hoc analysis of pooled daily e-diary data from patients with moderately to severely active UC receiving etrasimod or placebo in the phase III ELEVATE UC 52 and ELEVATE UC 12 trials. During the 12-week induction periods, patients self-reported stool frequency and rectal bleeding on days 1-28. Daily symptomatic response and symptomatic remission were calculated (partial modified Mayo Score). Results: Overall, 787 patients (527 receiving etrasimod, 260 placebo) were included in the analysis. Etrasimod-treated patients had statistically significantly higher rates of symptomatic response and symptomatic remission during the first 28 days of therapy, with adjusted differences (95% CIs) reaching statistical significance from day 2 (5.6% [0.8-10.3], P = .022) to day 11 (4.7% [0.4-9.0], P = .034), respectively. In patients naïve to biologic/Janus kinase inhibitor therapy, symptomatic response was statistically significantly improved with etrasimod vs placebo from day 3 (8.9% [2.3-15.5], P = .008). Symptomatic improvement rates were similar with and without concomitant corticosteroid use. Conclusions: In this post-hoc analysis, improvements in UC symptoms occurred in patients receiving etrasimod vs placebo from as early as day 2. These findings indicate a rapid onset of symptomatic effect with etrasimod treatment for moderately to severely active UC. ClinicalTrials.gov numbers: NCT03945188, NCT03996369.
- 8 February 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (6) , 1075-1085
Open AccessRapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program
Introduction: Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We evaluated patient-reported symptomatic improvement from patients in the ELEVATE UC program. Methods: This study was a post-hoc analysis of pooled daily e-diary data from patients with moderately to severely active UC receiving etrasimod or placebo in the phase III ELEVATE UC 52 and ELEVATE UC 12 trials. During the 12-week induction periods, patients self-reported stool frequency and rectal bleeding on days 1-28. Daily symptomatic response and symptomatic remission were calculated (partial modified Mayo Score). Results: Overall, 787 patients (527 receiving etrasimod, 260 placebo) were included in the analysis. Etrasimod-treated patients had statistically significantly higher rates of symptomatic response and symptomatic remission during the first 28 days of therapy, with adjusted differences (95% CIs) reaching statistical significance from day 2 (5.6% [0.8-10.3], P = .022) to day 11 (4.7% [0.4-9.0], P = .034), respectively. In patients naïve to biologic/Janus kinase inhibitor therapy, symptomatic response was statistically significantly improved with etrasimod vs placebo from day 3 (8.9% [2.3-15.5], P = .008). Symptomatic improvement rates were similar with and without concomitant corticosteroid use. Conclusions: In this post-hoc analysis, improvements in UC symptoms occurred in patients receiving etrasimod vs placebo from as early as day 2. These findings indicate a rapid onset of symptomatic effect with etrasimod treatment for moderately to severely active UC. ClinicalTrials.gov numbers: NCT03945188, NCT03996369.
- Open Access
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1016-1033
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis
Introduction While the therapeutic options for Crohn’s disease (CD) have broadened swiftly, direct comparative evidence on treatment efficacy remains limited. This study explored the relative efficacy and safety of available treatments based on current evidence. Methods A network meta-analysis (frequentist random-effect model) evaluated comparative efficacy of licensed advanced therapies for CD using data on efficacy of maintenance therapy from fully published, randomised, controlled phase 3/3b studies with 48–64-week follow-up periods and placebo or active comparator controls, identified through a systematic literature review (PROSPERO number CRD42023413752). Intravenous (IV) and subcutaneous (SC) infliximab, SC adalimumab, IV and SC vedolizumab, SC ustekinumab, SC risankizumab, and oral upadacitinib were included. Clinical remission and endoscopic response rates attained through maintenance regimens were assessed according to line of use (e.g., first-line and second-or-later line). Safety (serious adverse event rates) was also compared. Results Data from nine randomised controlled trials were analysed. SC infliximab 120 mg every 2 weeks (q.2.w.) exhibited the highest risk difference (95% confidence interval) vs. placebo in both first-line and second-or-later-line maintenance treatment for achieving clinical remission (0.38 [0.23–0.53] and 0.51 [0.19–0.83], respectively; 14 and 12 comparator arms, respectively), and endoscopic response (0.39 [0.29–0.49] and 0.35 [0.07–0.63], respectively; 5 comparator arms) compared with other treatments. Differences between therapies did not reach statistical difference. Safety was comparable among treatments in terms of rates of serious adverse events. Conclusions The current NMA integrating recently updated phase 3 data in CD indicated that no single treatment significantly outperformed others in achieving clinical remission and endoscopic response, although SC infliximab 120 mg q.2.w exhibited highest numerical efficacy as both a first-line and second-or-later-line maintenance treatment in adult patients with moderate-to-severe CD.
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1016-1033
Open AccessComparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis
Introduction While the therapeutic options for Crohn’s disease (CD) have broadened swiftly, direct comparative evidence on treatment efficacy remains limited. This study explored the relative efficacy and safety of available treatments based on current evidence. Methods A network meta-analysis (frequentist random-effect model) evaluated comparative efficacy of licensed advanced therapies for CD using data on efficacy of maintenance therapy from fully published, randomised, controlled phase 3/3b studies with 48–64-week follow-up periods and placebo or active comparator controls, identified through a systematic literature review (PROSPERO number CRD42023413752). Intravenous (IV) and subcutaneous (SC) infliximab, SC adalimumab, IV and SC vedolizumab, SC ustekinumab, SC risankizumab, and oral upadacitinib were included. Clinical remission and endoscopic response rates attained through maintenance regimens were assessed according to line of use (e.g., first-line and second-or-later line). Safety (serious adverse event rates) was also compared. Results Data from nine randomised controlled trials were analysed. SC infliximab 120 mg every 2 weeks (q.2.w.) exhibited the highest risk difference (95% confidence interval) vs. placebo in both first-line and second-or-later-line maintenance treatment for achieving clinical remission (0.38 [0.23–0.53] and 0.51 [0.19–0.83], respectively; 14 and 12 comparator arms, respectively), and endoscopic response (0.39 [0.29–0.49] and 0.35 [0.07–0.63], respectively; 5 comparator arms) compared with other treatments. Differences between therapies did not reach statistical difference. Safety was comparable among treatments in terms of rates of serious adverse events. Conclusions The current NMA integrating recently updated phase 3 data in CD indicated that no single treatment significantly outperformed others in achieving clinical remission and endoscopic response, although SC infliximab 120 mg q.2.w exhibited highest numerical efficacy as both a first-line and second-or-later-line maintenance treatment in adult patients with moderate-to-severe CD.
- Open Access
Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis—EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol
Introduction: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). While etrasimod demonstrated efficacy in randomised controlled trials, understanding its effectiveness in an observational setting is crucial. Methods and analysis: EFFECT-UC is a prospective, multinational, non-interventional study to evaluate the real-world effectiveness of etrasimod in adults with moderately to severely active UC. The study consists of a 52-week treatment period and a 28-day safety follow-up period and aims to enrol ~300 patients per cohort. Eligible patients (18–64 years) are advanced therapy naïve or experienced and are initiating etrasimod in a real-world clinical setting. Treatment will be guided independently by the clinician’s judgement. Patient-reported outcomes will be collected electronically throughout the study and daily for the first 2 weeks. Exploratory data, including faecal calprotectin, endoscopy and intestinal ultrasound, will be collected at predefined visits or during standard care. Primary endpoints are symptomatic remission at week 12 and week 52. Secondary endpoints include patient-reported outcome 2 (combined rectal bleeding and stool frequency subscores) response at week 12 and week 52 and corticosteroid-free symptomatic remission at week 52. Ethics and dissemination: Ethics approval was obtained for all sites. Recruitment is underway for cohort 1, comprising patients from the UK, Germany and Canada. Interim results for this cohort are expected in 2026 and final results in 2028; these will be submitted for publication in peer-reviewed journals and presented at appropriate congresses. Trial registration number: NCT06294925 .
Open AccessEffectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis—EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol
Introduction: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). While etrasimod demonstrated efficacy in randomised controlled trials, understanding its effectiveness in an observational setting is crucial. Methods and analysis: EFFECT-UC is a prospective, multinational, non-interventional study to evaluate the real-world effectiveness of etrasimod in adults with moderately to severely active UC. The study consists of a 52-week treatment period and a 28-day safety follow-up period and aims to enrol ~300 patients per cohort. Eligible patients (18–64 years) are advanced therapy naïve or experienced and are initiating etrasimod in a real-world clinical setting. Treatment will be guided independently by the clinician’s judgement. Patient-reported outcomes will be collected electronically throughout the study and daily for the first 2 weeks. Exploratory data, including faecal calprotectin, endoscopy and intestinal ultrasound, will be collected at predefined visits or during standard care. Primary endpoints are symptomatic remission at week 12 and week 52. Secondary endpoints include patient-reported outcome 2 (combined rectal bleeding and stool frequency subscores) response at week 12 and week 52 and corticosteroid-free symptomatic remission at week 52. Ethics and dissemination: Ethics approval was obtained for all sites. Recruitment is underway for cohort 1, comprising patients from the UK, Germany and Canada. Interim results for this cohort are expected in 2026 and final results in 2028; these will be submitted for publication in peer-reviewed journals and presented at appropriate congresses. Trial registration number: NCT06294925 .
- Open Access
- 26 September 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (1) , 77-86
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Background: We evaluated the efficacy and safety of ozanimod after 5-aminosalicylic acid (5-ASA) failure in advanced therapy (AT)–naive patients with moderate ulcerative colitis (UC) in True North and its open-label extension (OLE). Methods: True North was a randomized, 52-week, phase 3 trial with an optional OLE. Efficacy was assessed in True North and the OLE; safety was assessed through OLE week 190. Results: Overall, 203 AT-naive True North patients had moderate UC (Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1). Of these, 139 were also immunomodulator-naive and not receiving corticosteroids (5-ASA–exposed only) at baseline. Patients with moderate UC receiving ozanimod vs placebo achieved greater efficacy rates for all week 10 and week 52 outcomes, regardless of prior immunomodulator/corticosteroid use (eg, week 10 clinical remission: AT-naive = 36.8% vs 10.6%; 5-ASA–exposed only = 37.9% vs 17.2%). Higher symptomatic response rates were achieved by week 2 with ozanimod in AT-naive patients with moderate UC vs the overall AT-naive population (50.5% vs 38.7%); similar trends were observed in patients exposed only to 5-ASA. Efficacy was maintained through OLE week 190 in patients who entered OLE as True North week 52 ozanimod clinical responders. Of those entering OLE as True North week 10 ozanimod clinical nonresponders, 69.0% of AT-naive patients and 68.4% of patients exposed only to 5-ASA achieved symptomatic response by week 5. No new safety signals emerged. Conclusions: Ozanimod was safe, effective, and durable up to ∼5 years in AT-naive patients with moderate UC who failed conventional therapy. ClinicalTrials.gov: NCT02435992, NCT02531126.
- 26 September 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (1) , 77-86
Open AccessLong-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Background: We evaluated the efficacy and safety of ozanimod after 5-aminosalicylic acid (5-ASA) failure in advanced therapy (AT)–naive patients with moderate ulcerative colitis (UC) in True North and its open-label extension (OLE). Methods: True North was a randomized, 52-week, phase 3 trial with an optional OLE. Efficacy was assessed in True North and the OLE; safety was assessed through OLE week 190. Results: Overall, 203 AT-naive True North patients had moderate UC (Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1). Of these, 139 were also immunomodulator-naive and not receiving corticosteroids (5-ASA–exposed only) at baseline. Patients with moderate UC receiving ozanimod vs placebo achieved greater efficacy rates for all week 10 and week 52 outcomes, regardless of prior immunomodulator/corticosteroid use (eg, week 10 clinical remission: AT-naive = 36.8% vs 10.6%; 5-ASA–exposed only = 37.9% vs 17.2%). Higher symptomatic response rates were achieved by week 2 with ozanimod in AT-naive patients with moderate UC vs the overall AT-naive population (50.5% vs 38.7%); similar trends were observed in patients exposed only to 5-ASA. Efficacy was maintained through OLE week 190 in patients who entered OLE as True North week 52 ozanimod clinical responders. Of those entering OLE as True North week 10 ozanimod clinical nonresponders, 69.0% of AT-naive patients and 68.4% of patients exposed only to 5-ASA achieved symptomatic response by week 5. No new safety signals emerged. Conclusions: Ozanimod was safe, effective, and durable up to ∼5 years in AT-naive patients with moderate UC who failed conventional therapy. ClinicalTrials.gov: NCT02435992, NCT02531126.
- 2 September 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (9)
Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study
Background and Aims: We conducted a prospective study (FAVOUR) of patients with ulcerative colitis (UC) commencing vedolizumab to investigate fecal vedolizumab loss and its impact on serum levels and treatment outcomes. Methods: FAVOUR recruited patients with moderate-to-severe UC commencing vedolizumab. Fecal vedolizumab levels (FVL) were measured at days 1, 4, and 7 and at weeks 2, 6, and 14. Trough serum vedolizumab levels (SVL) were measured at weeks 2, 6, and 14. Results: In total, 36 patients were recruited, of whom 33 completed induction therapy. Fecal vedolizumab was detectable in 80/203 (39%) samples. Statistically significant, positive correlations were observed between FVL and clinical, biochemical, baseline endoscopic, and histologic disease activity at day 1, 4, and 7 as well as weeks 2 and 6. Week 14 clinical non-responders had higher FVL than responders at that timepoint (median 1.0 vs 0.0 µg/g, P = .004) but not at other timepoints. Area-under-the-curve analysis of FVL was used to quantify cumulative vedolizumab stool loss. This demonstrated significant differences between week 14 clinical responders and non-responders (44 µg/g/day, 95% CI: 0-128 vs 233 µg/g/day, 95% CI 0-1139, P < .0001), as well as between endoscopic responders and non-responders (48 µg/g/day, 95% CI 0-142 vs 179 µg/g/day, 95% CI 0-142, P = .0017), with non-responders having a higher rate of cumulative loss. Conclusions: Active UC results in fecal loss of vedolizumab. This correlates with lower SVL and decreased response to treatment. Fecal loss of vedolizumab may be a marker of disease activity and/or result in lower rates of drug exposure at a tissue level, negatively impacting response.
- 2 September 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (9)
Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study
Background and Aims: We conducted a prospective study (FAVOUR) of patients with ulcerative colitis (UC) commencing vedolizumab to investigate fecal vedolizumab loss and its impact on serum levels and treatment outcomes. Methods: FAVOUR recruited patients with moderate-to-severe UC commencing vedolizumab. Fecal vedolizumab levels (FVL) were measured at days 1, 4, and 7 and at weeks 2, 6, and 14. Trough serum vedolizumab levels (SVL) were measured at weeks 2, 6, and 14. Results: In total, 36 patients were recruited, of whom 33 completed induction therapy. Fecal vedolizumab was detectable in 80/203 (39%) samples. Statistically significant, positive correlations were observed between FVL and clinical, biochemical, baseline endoscopic, and histologic disease activity at day 1, 4, and 7 as well as weeks 2 and 6. Week 14 clinical non-responders had higher FVL than responders at that timepoint (median 1.0 vs 0.0 µg/g, P = .004) but not at other timepoints. Area-under-the-curve analysis of FVL was used to quantify cumulative vedolizumab stool loss. This demonstrated significant differences between week 14 clinical responders and non-responders (44 µg/g/day, 95% CI: 0-128 vs 233 µg/g/day, 95% CI 0-1139, P < .0001), as well as between endoscopic responders and non-responders (48 µg/g/day, 95% CI 0-142 vs 179 µg/g/day, 95% CI 0-142, P = .0017), with non-responders having a higher rate of cumulative loss. Conclusions: Active UC results in fecal loss of vedolizumab. This correlates with lower SVL and decreased response to treatment. Fecal loss of vedolizumab may be a marker of disease activity and/or result in lower rates of drug exposure at a tissue level, negatively impacting response.